Analysis of the GDC-SKCM cohort indicated that neither the mutational status nor the level of expression of the major validated MM drivers BRAF, NRAS, or NF1 provided useful prognostic information, in agreement with a recent report showing that, counterintuitively, the mutation or overexpression of verified oncogenes is rarely associated with poor prognosis in human cancers [20]. This evidence concerns the gene NRAS and Miyoshi myopathy.